Clinical Trials Logo

Grade II/III Glioma clinical trials

View clinical trials related to Grade II/III Glioma.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT02766270 Recruiting - Grade II/III Glioma Clinical Trials

CCRT With Temozolomide Versus RT Alone in Patients With IDH Wild-type/TERT Promoter Mutation Grade II/III Gliomas

Start date: September 26, 2016
Phase: N/A
Study type: Interventional

The management of lower-grade gliomas (Diffuse low-grade and intermediate-grade gliomas, WHO II and III) is largely based on surgery followed by radiotherapy. Recent studies showed that lower-grade glioma patients with IDH wild-type (IDH-wt) and TERT promoter mutation (TERTp-mut) had dismal clinical outcomes. These results suggested that current treatment strategies are not adequate for this subtype of lower-grade glioma. The present study aims to examine the efficacy and safety of concurrent chemoradiotherapy with temozolomide followed by adjuvant temozolomide for lower- grade glioma patients with IDH-wt and TERTp-mut.